 Ovarian Neoplasms
"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 2 | 6 | | 1997 | 1 | 0 | 1 | | 1998 | 3 | 0 | 3 | | 1999 | 1 | 1 | 2 | | 2000 | 2 | 0 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 3 | 1 | 4 | | 2004 | 3 | 1 | 4 | | 2005 | 4 | 1 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 8 | 0 | 8 | | 2008 | 9 | 2 | 11 | | 2009 | 3 | 1 | 4 | | 2010 | 7 | 5 | 12 | | 2011 | 15 | 3 | 18 | | 2012 | 12 | 1 | 13 | | 2013 | 13 | 1 | 14 | | 2014 | 10 | 1 | 11 | | 2015 | 21 | 2 | 23 | | 2016 | 27 | 2 | 29 | | 2017 | 14 | 0 | 14 | | 2018 | 13 | 5 | 18 | | 2019 | 23 | 0 | 23 | | 2020 | 30 | 1 | 31 | | 2021 | 23 | 2 | 25 | | 2022 | 23 | 1 | 24 | | 2023 | 20 | 0 | 20 | | 2024 | 19 | 3 | 22 | | 2025 | 16 | 0 | 16 | | 2026 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Chen XL, Tharp KM, Ojalill M, Ozmadenci D, Boyer A, Haanen TJ, Lawson C, Lee HJ, Xia M, Tahon E, Zhang Y, Minor C, Khan SU, Anderson CC, Nemkov T, Rose M, Estrada MV, Molinolo AA, Warren E, Penalosa P, Eskander RN, McHale MT, Wang SE, Connolly DC, Fisch KM, Stupack DG, Schlaepfer DD. FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages. Cell Rep. 2026 Mar 24; 45(3):117009.
-
Hollis RL, Miller A, Lankes HA, Wong KK, Rodgers W, Millan D, Carty K, Coleman RL, Moore KN, Alvarez Secord A, O'Malley DM, Chan JK, Hagemann AR, Gaillard S, Guntupalli SR, Edelson MI, Rose PG, Dorigo O, Banerjee S, Ewing A, Churchman M, Sood AK, Herrington CS, Gourley C, Gershenson DM. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. Clin Cancer Res. 2026 Feb 17; 32(4):724-734.
-
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Dev. 2026 02 02; 40(3-4):199-214.
-
Sakitis CJ, Laborde J, Wrobel J, Soupir AC, Colin-Leitzinger CM, Bitler BG, Townsend MK, Lawson AB, Schildkraut JM, Tworoger SS, Terry KL, Peres LC, Fridley BL. Bayesian multi-cell type models for the analysis of complex immune cell populations with application to ovarian cancer. Brief Bioinform. 2026 Jan 07; 27(1).
-
Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A, Stebbing J, Joshi B, Bourdelais S, Delepine C, Chand D, Wu W, Johnson B, Grossman JE, O'Day SJ, Matulonis UA, Gordon MS. Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer. 2025 Dec 23; 13(12).
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
-
Bitler BG, Lang J, Nunez-Avellaneda D, Behbakht K, Davidson NR, Woodruff ER, Villagomez FR. Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. Sci Rep. 2025 Nov 10; 15(1):39257.
-
Lawson-Michod KA, Johnson CE, Barnard ME, Davidson NR, Collin LJ, Nix DA, Huff CD, Berchuck A, Salas LA, Greene CS, Marks JR, Peres LC, Doherty JA, Schildkraut JM. Homologous Recombination Deficiency and Survival in Ovarian High-Grade Serous Carcinoma by Self-Reported Race. Cancer Epidemiol Biomarkers Prev. 2025 Nov 03; 34(11):2007-2014.
-
Liang B, Tenney TB, Han L, Zhang X, Wang A, Barry-Holson KQ, Rosenzweig ER, Toland AMS, Diver EJ, Deutschman E, Method M, Sloss CM, Yang EJ, Charu V, Howitt BE. Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma. Int J Gynecol Pathol. 2026 Jan 01; 45(1):9-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|